Bristol exec hints of Onglyza launch strategy

Now that AstraZeneca and Bristol-Myers Squibb have the EMEA's nod on Onglyza, they're revving up to launch the new diabetes remedy. First target: Germany. Timing: By the end of this quarter. Now, the companies are still waiting for the European Commission to ratify the EMEA's decision, so the anticipation may be a bit premature. But no one has launched a drug successfully without a plan, have they?

In a press briefing in Frankfurt yesterday, Bristol's German chief Han Steutel gave a hint of the partnership's sales strategy, too. As Bloomberg notes, Steutel leaned heavily on Onglyza's side-effect profile. Or, rather, on the side effects of Onglyza's competitors: "The products which are currently on the market have side effects" such as weight gain and lower-than-normal blood glucose, he said. Onglyza doesn't.

Analysts are already salivating over Onglyza's potential boost for both companies. A Citigroup pharma-watcher pegged U.S. peak sales for the drug at $1 billion in a note to investors yesterday. (That's if and when the FDA approves it, which hasn't happened yet.) Steutel wouldn't put a number to it, but if U.S. sales reach blockbuster levels, then worldwide sales would be much bigger. The companies should get a good indication of its overall uptake once it launches in Germany; that country is the biggest European market for diabetes treatments.

- read the Bloomberg piece 

Suggested Articles

With AbbVie's two most recent launches outperforming expectations, investors could be looking at a steal with an Allergan merger looming.

Investors are clamoring for a CVR created in the BMS-Celgene deal, but it will only pay off if the FDA approves three hot pipeline projects.

Muzammil Mansuri, Sanofi’s EVP of strategy and business development since February 2016, is retiring at the end of November.